Why Merck rolled the dice on an ‘unbelievable’ early-stage brain cancer drug

Merck & Co.’s recent $1.3 billion deal to reel in Modifi Biosciences seemed to ignore pharma’s common dealmaking wisdom. It targets an early-stage, aka riskier, asset, and it’s in glioblastoma, a challenging therapeutic area plagued with drug failures.